{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-219801","form_type":"8-K","ticker":"BBOT","cik":"0001869105","company_name":"BridgeBio Oncology Therapeutics, Inc.","filed_at":"2026-05-12T21:07:04+00:00","discovered_at":"2026-05-12T21:08:00.316419+00:00","generated_at":"2026-05-12T21:21:26.161529+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BBOT Q1 net loss widens to $42.1M; cash $388.9M funds ops into 2028; pipeline shows early efficacy","bullets":["Net loss $42.1M vs $22.1M YoY; R&D spend $39.8M on advancing three RAS programs.","Cash, equivalents and marketable securities $388.9M as of March 31, 2026; runway into 2028.","BBO-8520 monotherapy ORR 65% in KRAS G12C NSCLC; BBO-11818 partial response in pancreatic cancer.","BBO-10203 achieved target engagement with no hyperglycemia; clinical benefit in CRC and HR+ BC.","Pedro Beltran appointed CEO, Idan Elmelech COO effective April 20, 2026; Neil Kumar Executive Chairman."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-219801","json":"https://secwatch.observer/filing/0001193125-26-219801.json","markdown":"https://secwatch.observer/filing/0001193125-26-219801.md","text":"https://secwatch.observer/filing/0001193125-26-219801.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526219801/0001193125-26-219801-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526219801/bbot-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T21:21:26.161529+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"74ed2439c13266306efaa7931974b3bf5cde0d84","claim":"BridgeBio Oncology Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $42.1 million for the first quarter of 2026 compared to $22.1 million for the first qu.","evidence_excerpt":"BridgeBio Oncology Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526219801/0001193125-26-219801-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Net income","value":"Net loss was $42.1 million for the first quarter of 2026 compared to $22.1 million for the first qu"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}